Newsletter Subscribe
Enter your email address below and subscribe to our newsletter

youtube+1kucoin+1cryptobriefing+1Neuralink announced on June 30 that it had successfully inserted ultra-thin electrode threads directly through the dura mater — the brain's tough protective membrane — without cutting it open, a first in the company's clinical trials. The procedure, which took place in May 2026, eliminates a key surgical step that has long been standard in brain-computer interface implantation.youtube+1
In a video posted by Neuralink, the company explained that its robotic insertion device pushed polyimide-based electrode threads, thinner than a human hair, through the intact dura and into the cerebral cortex while actively avoiding blood vessels. Previously, surgeons had to cut away the dura to expose the brain before electrode placement.instagram+1
The dura mater can be more than 10 times thicker than Neuralink's electrode threads, making the transdural approach a technical challenge the company says it has now overcome. By leaving the membrane intact, the procedure theoretically reduces infection risk, minimizes surgical trauma, and could shorten recovery times.kucoin+1
The surgery was performed at Toronto Western Hospital, which has served as the exclusive Canadian site for Neuralink's CAN-PRIME clinical trial since Health Canada approved the study in late 2024. Surgeons at that facility had already demonstrated rapid results: when the first Canadian patients received implants in August and September 2025, neurosurgeon Andres Lozano reported that one participant could operate a cursor "simply by thinking within minutes" of surgery.finance.yahoo+2
Elon Musk highlighted the transdural milestone on June 30, calling it a transformative step for the safety and simplicity of brain-computer interfaces. The announcement follows remarks Musk made on May 18 at Israel's Samson International Smart Mobility Summit, where he described Neuralink's work as "Jesus-level technologies" and "miracles in the scientific sense," pointing to the company's goals of restoring mobility to people with tetraplegia and giving sight to the blind through its forthcoming Blindsight product.churchleaders+2
Neuralink, which is privately held, has now enrolled 21 human participants across its trials. At the end of 2025, Musk announced plans to begin high-volume production of brain-computer interface devices and move toward fully automated surgical procedures in 2026 — a vision the transdural technique brings closer to reality.businessinsider+2